|
List Of Cardiovascular Clinical Trials
This is a list of cardiovascular clinical trials, categorized and alphabetized. Acute coronary syndrome * International Studies of Infarct Survival (ISIS) - four randomized controlled trials of several drugs for treating suspected acute myocardial infarction. Arrhythmias * Cardiac Arrhythmia Suppression Trial (CAST) - randomized controlled trial designed to test the hypothesis that suppression of premature ventricular complexes (PVC) with class I antiarrhythmic agents after a myocardial infarction (MI) would reduce mortality. Atrial fibrillation Coronary artery disease Epidemiology * Busselton Health Study - a prospective cohort study of residents of the Western Australian city of Busselton regarding cardiovascular disease, pulmonary function, diabetes, and cancer. * Caerphilly Heart Disease Study - prospective cohort study of the residents from Caerphilly, South Wales, to examine relationships between a wide range of social, lifestyle, dietary, and other factors ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
International Studies Of Infarct Survival
The International Studies of Infarct Survival (ISIS) were four randomized controlled trials of several drugs for treating suspected acute myocardial infarction ("heart attack"). More than 134,000 patients from over 20 countries took part in four large simple trials between 1981 and 1993, coordinated from Oxford, England. ISIS-1 The First International Study of Infarct Survival (ISIS-1) was a placebo-controlled trial of the beta-blocker atenolol. It recruited 16,027 patients and was completed in 1985. ISIS-2 The Second International Study of Infarct Survival (ISIS-2) was a 2×2 factorial placebo-controlled trial of aspirin and the thrombolytic drug streptokinase. It recruited 17,187 patients and was completed in 1988. ISIS-3 The Third International Study of Infarct Survival (ISIS-3) was a 3×2 factorial trial that compared the three thrombolytic drugs streptokinase, tissue plasminogen activator (tPA) and anistreplase to each other, and also compared the anticoagulant heparin to n ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Systolic Blood Pressure Intervention Trial
The Systolic Blood Pressure Intervention Trial (SPRINT) is a multi-center clinical trial that was performed from 2010 to 2015, and published in November 2015. The objective of the trial was to identify whether, in patients with a systolic blood pressure (SBP) of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, treating to a systolic blood pressure target of less than 120 mm Hg is superior to a target of 140 mm Hg. The primary outcome being measured was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. The study implies that patients receiving "standard" therapy were controlled similarly to all adults being treated for hypertension and that patients receiving "intensive" therapy had a lower mean SBP compared to all adults being treated for hypertension, but neither conclusion is true when compared to the US National Health and Nutrition Examination Survey. During the study ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
West Of Scotland Coronary Prevention Study
The West of Scotland Coronary Prevention Study (also known as WOSCOPS) was a landmark randomized controlled trial, published in 1995, that investigated the effects of pravastatin, a cholesterol-lowering drug, on primary prevention of coronary heart disease (CHD) in men with hypercholesterolemia. Conducted in the early 1990s, this study provided critical evidence on the benefits of statins in reducing cardiovascular events in individuals without a history of CHD. It concluded that statin treatment reduced CHD events by 31% after nearly five years of treatment. Background Cardiovascular disease, particularly CHD, is a leading cause of death globally. High low-density lipoprotein (LDL) cholesterol levels are a well-established risk factor for developing CHD. While previous studies had demonstrated the benefits of lipid-lowering agents in patients with existing CHD, the WOSCOPS was one of the first large-scale trials to evaluate the efficacy of statins for primary prevention in indivi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Scandinavian Simvastatin Survival Study
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, Randomized controlled trial#Blinding, randomized, double-blind, Treatment and control groups, placebo-controlled clinical trial, which provided the initial data that supported the use of the statin, cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a myocardial infarction, heart attack or angina. The study was sponsored by the pharmaceutical company Merck & Co., Merck and enrolled 4,444 people from 94 centres in Scandinavia. Before the 4S study, it was not proven that lowering cholesterol could prolong life in people who had CHD. The study concluded that secondary prevention with simvastatin in a high risk group with CHD reduced overall mortality by 30%. Published in ''The Lancet'' in 1994, it is considered a "landmark paper". Objective The 4S multicentre, Randomized controlled trial ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PROVE-IT TIMI 22
The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the antibiotic gatifloxacin or placebo. The participants enrolled at 349 sites across Australia, Europe, and North America between November 2000 and December 2001, and the study concluded that statin treatment for secondary prevention reduced coronary heart disease (CHD) events and that atorvastatin had a more marked effect than pravastatin. The study was published in ''The New England Journal of Medicine'' and reported at the American College of Cardiology Annual Scientific Session in 2004. See also * Heart Protection Study (HPS) * Scandinavian Simvastatin Survival Study (4S ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
JUPITER Trial
The JUPITER trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial) was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels. Study rationale JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease. The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP). JUPITER was the first clinical trial to indicate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease."JUPITER: Usin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Heart Protection Study
The Heart Protection Study was a randomized controlled trial run by the Clinical Trial Service Unit, and funded by the Medical Research Council (MRC) and the British Heart Foundation (BHF) in the United Kingdom. It studied the use of the cholesterol lowering drug, simvastatin 40 mg and vitamin supplementation (vitamin E, vitamin C and beta carotene) in people who were at risk of cardiovascular disease. It was led by Jane Armitage, an epidemiologist at the Clinical Trial Service Unit. Results An outline of the study protocol was published in 1999. Initial results were published in 2002, which indicated that vitamins made little difference in modifying cardiovascular risk, but that simvastatin could significantly reduce the risk of cardiovascular events. Further publications, from 2003 and 2004, were concerned with the efficacy of simvastatin in diabetes patients and preventing stroke. A 2005 paper analyses the cost-effectiveness of a prescribing strategy similar to the on ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
HDL-Atherosclerosis Treatment Study
The HDL-Atherosclerosis Treatment Study, also known as HATS, was a three-year double-blind trial involving 160 people with coronary heart disease (CHD) who had a low HDL and near normal LDL. The study compared a combination of simvastatin and niacin with antioxidant vitamin therapy. Using angiography, coronary artery stenosis progressed when using placebo or antioxidant alone, and regressed with the combination of simvastatin and niacin. The study demonstrated a 90% reduction in CHD death, nonfatal heart attacks, stroke, or revascularization for worsening angina. It was published in 2001. See also * Heart Protection Study * Scandinavian Simvastatin Survival Study The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, Randomized controlled trial#Blinding, randomized, double-blind, Treatment and control groups, placebo-controlled clinical trial, which provided the initial ... References Epidemiological study projects Clinical trials related ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AIM-HIGH (trial)
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (also known as AIM-HIGH) was a randomized control trial designed to assess the efficacy of niacin (extended-release) added to statin therapy in reducing cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD). These patients had well-controlled low-density lipoprotein (LDL) cholesterol but persistently low high-density lipoprotein (HDL) cholesterol and elevated triglycerides. 3,414 patients with established ASCVD were enrolled. The mean follow-up period was three years. The trial was stopped early due to a lack of efficacy and a trend towards an increase in the incidence of ischemic stroke. Background Low HDL cholesterol and high triglycerides are recognized risk factors for cardiovascular disease, even in individuals with well-controlled LDL cholesterol. Niacin has been shown to increase HDL cholesterol and lower triglyce ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Antihypertensive And Lipid Lowering Treatment To Prevent Heart Attack Trial
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with hypertension. Participants were initially randomised to chlorthalidone (diuretic) versus doxazosin ( alpha-adrenergic blocker), lisinopril ( ACE-inhibitor), and amlodipine (calcium channel blocker). The doxazosin arm was discontinued early on in the trial because of a higher rate of combined cardiovascular events and admissions for heart failure compared with chlorthalidone. The study concluded that major CHD events did not differ between initial use of chlorthalidone versus lisinopril or amlodipine. As a result, the Joint National Committee (7) guidelines of 2003, recommended the cheaper but equally effective diuretics as a first line treatment for hypertension. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cardiac Arrhythmia Suppression Trial
The Cardiac Arrhythmia Suppression Trial (CAST) was a double-blind, randomized, controlled study designed to test the hypothesis that suppression of premature ventricular contraction, premature ventricular complexes (PVC) with class I antiarrhythmic agents after a myocardial infarction (MI) would reduce Mortality rate, mortality. It was conducted between 1986 and 1989 and included over 1700 patients in 27 centres. The study found that the tested drugs increased mortality instead of lowering it as was expected. The publication of these results in 1991/92, in combination with large follow-up studies for drugs that had not been tested in CAST, led to a paradigm shift in the treatment of MI patients. Class I and III antiarrhythmics are now only used with extreme caution after MI, or they are contraindicated completely. Background Study design The second Cardiac Arrhythmia Suppression Trial (CAST II) modified the enrollment criteria to include patients at higher risk for serious ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
RALES (trial)
The Randomized Aldactone Evaluation Study (RALES) trial is a landmark clinical study that assessed the impact of spironolactone, an aldosterone antagonist, on morbidity and mortality in patients with severe heart failure due to systolic dysfunction. The findings from this trial significantly influenced the treatment guidelines for heart failure. Background Heart failure, particularly with reduced ejection fraction (HFrEF), is a major cause of morbidity and mortality worldwide. Aldosterone, a hormone that promotes sodium retention and potassium excretion, plays a significant role in the pathophysiology of heart failure by contributing to fluid overload, myocardial fibrosis, and vascular damage. Spironolactone, a potassium-sparing diuretic Potassium-sparing diuretics or antikaliuretics refer to drugs that cause diuresis without causing potassium loss in the urine. They are typically used as an adjunct in management of hypertension, cirrhosis, and congestive heart failure. The st ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
